当前位置: X-MOL 学术N. Engl. J. Med. › 论文详情
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
The New England Journal of Medicine ( IF 70.670 ) Pub Date : 2020-03-26 , DOI: 10.1056/nejmoa1910182
M. Domenica Cappellini; Vip Viprakasit; Ali T. Taher; Pencho Georgiev; Kevin H.M. Kuo; Thomas Coates; Ersi Voskaridou; Hong-Keng Liew; Idit Pazgal-Kobrowski; G.L. Forni; Silverio Perrotta; Abderrahim Khelif; Ashutosh Lal; Antonis Kattamis; Efthymia Vlachaki; Raffaella Origa; Yesim Aydinok; Mohamed Bejaoui; P. Joy Ho; Lee-Ping Chew; Ping-Chong Bee; Soo-Min Lim; Meng-Yao Lu; Adisak Tantiworawit; Penka Ganeva; Liana Gercheva; Farrukh Shah; Ellis J. Neufeld; Alexis Thompson; Abderrahmane Laadem; Jeevan K. Shetty; Jun Zou; Jennie Zhang; Dimana Miteva; Tatiana Zinger; Peter G. Linde; Matthew L. Sherman; Olivier Hermine; John Porter; Antonio Piga

Background Patients with transfusion-dependent β-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor β superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of red-cell units transfused) in such patients. Methods In this randomized, double-blind, phase 3 trial, we assigned, in a 2:1 ratio, adults with transfusion-dependent β-thalassemia to receive best supportive care plus luspatercept (at a dose of 1.00 to 1.25 mg per kilogram of body weight) or placebo for at least 48 weeks. The primary end point was the percentage of patients who had a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval. Other efficacy end points included reductions in the transfusion burden during any 12-week interval and results of iron studies. Results A total of 224 patients were assigned to the luspatercept group and 112 to the placebo group. Luspatercept or placebo was administered for a median of approximately 64 weeks in both groups. The percentage of patients who had a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval was significantly greater in the luspatercept group than in the placebo group (21.4% vs. 4.5%, P<0.001). During any 12-week interval, the percentage of patients who had a reduction in transfusion burden of at least 33% was greater in the luspatercept group than in the placebo group (70.5% vs. 29.5%), as was the percentage of those who had a reduction of at least 50% (40.2% vs. 6.3%). The least-squares mean difference between the groups in serum ferritin levels at week 48 was −348 μg per liter (95% confidence interval, −517 to −179) in favor of luspatercept. Adverse events of transient bone pain, arthralgia, dizziness, hypertension, and hyperuricemia were more common with luspatercept than placebo. Conclusions The percentage of patients with transfusion-dependent β-thalassemia who had a reduction in transfusion burden was significantly greater in the luspatercept group than in the placebo group, and few adverse events led to the discontinuation of treatment. (Funded by Celgene and Acceleron Pharma; BELIEVE ClinicalTrials.gov number, NCT02604433; EudraCT number, 2015-003224-31.) VISUAL ABSTRACT Phase 3 Trial of Luspatercept for Transfusion-Dependent β-Thalassemia
更新日期:2020-03-26

 

全部期刊列表>>
全球疫情及响应:BMC Medicine专题征稿
欢迎探索2019年最具下载量的化学论文
新版X-MOL期刊搜索和高级搜索功能介绍
化学材料学全球高引用
ACS材料视界
南方科技大学
x-mol收录
南方科技大学
自然科研论文编辑服务
上海交通大学彭文杰
中国科学院长春应化所于聪-4-8
武汉工程大学
课题组网站
X-MOL
深圳大学二维材料实验室张晗
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug